Carna Biosciences
4572.TTSE GROWTHPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥579m | ¥636m | ¥1.6bn | ¥1.4bn | ¥2.0bn | ¥1.1bn |
| Operating income | −¥2.1bn | −¥2.1bn | −¥1.1bn | −¥1.3bn | −¥531m | — |
| Ordinary income | −¥2.1bn | −¥2.1bn | −¥1.1bn | −¥1.3bn | −¥523m | −¥1.1bn |
| Net income (owners) | −¥2.2bn | −¥2.2bn | −¥1.2bn | −¥1.3bn | −¥534m | −¥1.1bn |
| Total assets | ¥1.2bn | ¥2.8bn | ¥4.3bn | ¥4.3bn | ¥5.4bn | ¥4.8bn |
| Net assets / equity | ¥309m | ¥2.5bn | ¥3.9bn | ¥3.6bn | ¥4.3bn | ¥3.8bn |
| Operating cash flow | −¥2.2bn | −¥1.4bn | −¥1.7bn | −¥708m | −¥1.5bn | −¥1.3bn |
| EPS (basic) | ¥-113.62 | ¥-121.64 | ¥-68.62 | ¥-99.1 | ¥-42.1 | ¥-90.33 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 3
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 71 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 71 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 71 figures · EDINET |
22 more reports are still being processed.
Segments · FY ended 2025-12
| Segment | External sales | Profit |
|---|---|---|
| Drug Discovery Business | — | −¥2.0bn |
| Drug Discovery Support Business | ¥579m | −¥51m |
| Adjustments & eliminations | — | — |
| Total | ¥579m | −¥2.1bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.